Identification of a survivin-derived peptide that induces HLA-A*0201-restricted antileukemia cytotoxic T lymphocytes.
Siegel
S
S
Steinmann
J
J
Schmitz
N
N
Stuhlmann
R
R
Dreger
P
P
Zeis
M
M
D000208:Acute Disease; D000951:Antigens, Neoplasm / Q000276:immunology; D000970:Antineoplastic Agents / Q000276:immunology; D002478:Cells, Cultured; D015853:Cysteine Proteinase Inhibitors / Q000276:immunology; D015234:HLA-A Antigens / Q000276:immunology*; D015789:HLA-A2 Antigen; D006412:Hematopoietic Stem Cells / Q000276:immunology; D006801:Humans; D051034:Inhibitor of Apoptosis Proteins; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000276:immunology*; D007951:Leukemia, Myeloid / Q000276:immunology*; D008869:Microtubule-Associated Proteins / Q000276:immunology*; D009363:Neoplasm Proteins; D010446:Peptide Fragments / Q000276:immunology*; D000077022:Survivin; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology*
D000951:Antigens, Neoplasm; D000970:Antineoplastic Agents; C107489:BIRC5 protein, human; D015853:Cysteine Proteinase Inhibitors; D015234:HLA-A Antigens; C435939:HLA-A*02:01 antigen; D015789:HLA-A2 Antigen; D051034:Inhibitor of Apoptosis Proteins; D008869:Microtubule-Associated Proteins; D009363:Neoplasm Proteins; D010446:Peptide Fragments; D000077022:Survivin